HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

被引：0
|
作者：
Mateos, Maria-Victoria
Oriol, Albert
Larocca, Alessandra
Blade, Joan
Cavo, Michele
Rodriguez Otero, Paula
Leleu, Xavier
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Alegre, Adrian
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Harmenberg, Johan
Zavisic, Stojan
Thuresson, Sara
Ohman, Oskar
Richardson, Paul G.
机构：
[1] Univ Hosp Salamanca, Canc Res Ctr IBMCC USAL CSIC, IBSAL, Salamanca, Spain
[2] Hosp Badalona Germans Trias & Pujol, Inst Invest Leucemia Josep Carreras, Badalona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Inst Catela Oncol, Badalona, Spain
[4] AOU Citta Salute & Sci Torino SC, Ematol u, Torin, Italy
[5] Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain
[6] St Orsola Marcello Malpighi Hosp, Bologna, Italy
[7] Clin Univ Navarra Pamploma, Navarra, Spain
[8] CHU Poitiers, Poitiers, France
[9] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[10] Mem Sloan Kettering Canc, Myeloma Serv, Dept Med, New York, NY USA
[11] Ctr Hosp Univ, Nantes, France
[12] Hosp Univ La Princesa, Madrid, Spain
[13] Assoc Med Onc, Bolingbrook, IL USA
[14] Baylor Scott & White Charles A Sammons Canc Ctr, Dallas, TX USA
[15] Oncol Inst Hope & Innovat, Glendale, CA USA
[16] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[17] Oncopeptides AB, Stockholm, Sweden
[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20570
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
    Nadeem, Omar
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Creixenti, Joan Blade
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Sandberg, Anna
    Pelaez, Ivonne
    Jaques, Christian
    Orre, Marie
    Cavo, Michele
    BLOOD, 2020, 136
  • [2] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zamagni, Elena
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Creixenti, Joan Blade
    BLOOD, 2020, 136
  • [3] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN 55 PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH EXTRAMEDULLARY DISEASE (EMD)-SUBGROUP ANALYSIS
    Zamagni, E.
    Richardson, P. G.
    Mateos, M. V.
    Oriol, A.
    Larocca, A.
    Cavo, M.
    Rodriguez-Otero, P.
    Leleu, X.
    Norkin, M.
    Nadeem, O.
    Hiemenz, J. W.
    Hassoun, H.
    Touzeau, C.
    Alegre, A.
    Paner, A.
    Maisel, C.
    Mazumder, A.
    Raptis, A.
    Puig, N.
    Thuresson, M.
    Harmenberg, J.
    Harlin, O.
    Blade, J.
    HAEMATOLOGICA, 2021, 106 (10) : 14 - 14
  • [4] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
    Oriol, Albert
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Larocca, Alessandra
    Creixenti, Joan Blade
    Cavo, Michele
    Rodriguez-Otero, Paula
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Strang, Peter
    Sandberg, Anna
    Jaques, Christian
    Thuresson, Marcus
    Orre, Marie
    Leleu, Xavier
    BLOOD, 2020, 136
  • [5] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Creixenti, Joan Blade
    Cavo, Michele
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [6] Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Bringhen, Sara
    Richardson, Paul G.
    Voorhees, Peter Michael
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Zonder, Jeffrey A.
    Reeves, Brandi Nikcole
    Zavisic, Stojan
    Harmenberg, Johan
    Obermueller, Jakob
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agner
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zamagni, Elena
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Blade, Joan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S427 - S427
  • [8] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Moreb, Jan
    Blade, Joan
    Hassoun, Hani
    Cavo, Michele
    Alegre, Adrian
    Mazumder, Amitabha
    Maisel, Christopher
    Paner, Agne
    Leleu, Xavier
    Zonder, Jeffrey A.
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CANCER RESEARCH, 2019, 79 (13)
  • [9] HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients
    Larocca, Alessandra
    Richardson, Paul G.
    Oriol, Albert
    Creixenti, Joan Blade
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Thuresson, Marcus
    Harmenberg, Johan
    Gustavsson, Bengt
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [10] HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients With Relapsed/Refractory Multiple Myeloma With Extramedullary Disease-Subgroup Analysis
    Richardson, Paul
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zamagni, Elena
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Blade, Joan
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S10
12345